Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Elicio Therapeutics Inc. (ELTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ELTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -43.63% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.52M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 42094 | Beta - | 52 Weeks Range 3.34 - 11.45 | Updated Date 04/2/2025 |
52 Weeks Range 3.34 - 11.45 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.44 |
Earnings Date
Report Date 2025-03-27 | When Before Market | Estimate -0.875 | Actual -1.02 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -73.7% | Return on Equity (TTM) -353.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78550469 | Price to Sales(TTM) - |
Enterprise Value 78550469 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 15861900 | Shares Floating 6771970 |
Shares Outstanding 15861900 | Shares Floating 6771970 | ||
Percent Insiders 43.86 | Percent Institutions 7.16 |
Analyst Ratings
Rating 4 | Target Price 9.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Elicio Therapeutics Inc.
Company Overview
History and Background
Elicio Therapeutics Inc. is a biotechnology company focused on developing immunotherapies based on its Amphiphile (AMP) platform. Founded with the goal of enhancing the delivery of immunogens to the lymphatic system, leading to potent and durable immune responses. Elicio Therapeutics is still in the clinical stage of testing.
Core Business Areas
- Immuno-oncology: Developing immunotherapies for the treatment of various cancers by activating and directing the immune system to target tumor cells.
- Infectious Diseases: Exploring the application of its AMP platform in the development of vaccines and therapies for infectious diseases.
Leadership and Structure
The leadership team consists of seasoned executives and scientists with expertise in immunotherapy and drug development. The organizational structure appears to be typical for a clinical-stage biotech company, with functional departments covering research, clinical development, manufacturing, and business operations.
Top Products and Market Share
Key Offerings
- ELI-002: ELI-002 2P is an Amphiphile (AMP) mKRAS-targeted cancer vaccine designed to target mutated KRAS-driven cancers. The company has begun Phase 1/2 clinical trials evaluating the therapy as a single agent and in combination with pembrolizumab. Competitors include companies developing other cancer vaccines and targeted therapies for KRAS-mutated cancers.
- ELI-004: ELI-004 is an Amphiphile (AMP) mRAS cancer vaccine designed to target multiple mutated RAS-driven cancers. The company has plans to start a Phase 1/2 clinical trial. Competitors include companies developing other cancer vaccines and targeted therapies for RAS-mutated cancers.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing rapid growth, driven by advances in our understanding of the immune system and the development of novel therapeutic modalities. This includes cancer vaccines and targeted immune activators. The trend is towards personalized medicine and therapies that enhance the body's natural ability to fight disease.
Positioning
Elicio Therapeutics is positioned as a clinical-stage biotechnology company focused on innovative immunotherapies using its AMP platform. Its competitive advantage lies in the potential of its technology to enhance immune responses through targeted delivery to the lymphatic system.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is substantial, projected to reach billions of dollars in the coming years. Elicio's positioning and future offerings, if clinically successful, could capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Novel AMP platform technology
- Targeted immunotherapy approach
- Experienced leadership team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources (typical for clinical-stage biotech)
- Dependence on clinical trial success
- Potential for competition from larger pharmaceutical companies
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of AMP platform to new therapeutic areas
- Positive clinical trial results
- Advancements in immunotherapy research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established immunotherapies
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- GILD
- BMY
Competitive Landscape
Elicio Therapeutics competes with established pharmaceutical companies and biotechnology firms in the immuno-oncology space. Its competitive advantage is based on its novel AMP platform, which can enhance immune responses. Disadvantages include limited financial resources and the need to demonstrate clinical efficacy and safety.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical development and early-stage clinical trials. Significant revenue growth is dependent on positive clinical data and partnerships.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and strategic partnerships. Analyst estimates will become more relevant as the company progresses through clinical development.
Recent Initiatives: Recent initiatives focus on advancing its clinical programs for ELI-002 and ELI-004. Expanding its pipeline through internal research and development and potential collaborations.
Summary
Elicio Therapeutics is a clinical-stage biotechnology company with a promising AMP platform for developing immunotherapies. The company has potential in cancer treatments. However, Elicio is highly reliant on clinical trial outcomes and must effectively manage cash flow and partnerships to thrive amid larger competitors. Positive clinical results and strategic collaborations are key to future success.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
BNTX
BioNTech SE
BNTX
BioNTech SE
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRNA
Moderna Inc
MRNA
Moderna Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and is subject to change. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President, Principal Accounting Officer & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://elicio.com |
Full time employees 32 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node"targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.